DIVISLAB · NSE
Divi's Laboratories Limited
₹9,375
+0.56% (+₹52)
Prev. close
₹9,323
Volume
6,91,534
Delivery %
71.3%
As of
18 Sept 2026
Price history
Chandan Taparia · Motilal Oswal Financial Services Ltd · 08 Sept 2026
“Bullish on Divis Laboratories with a target price of ₹9,800 and a stop loss of ₹9,050. The stock is in an overall uptrend, trading near all-time highs, respecting its 10 EMA, and showing buying interest with a bullish Marubozu candle, suggesting a move towards fresh highs above ₹9,300.”
Entry ≈ ₹9,364.5 (first trade after call)Target ₹9,800 (+4.7%)Stop ₹9,050 (-3.4%)R:R ~1.4:1Stopped out · 16 Sept 2026
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Divis Laboratories with a target price of ₹9,800 and a stop loss of ₹9,050. The stock is in an overall uptren…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Divis Laboratories | PENDING | ||||
“Bullish on Divis Laboratories with a target price of ₹9,800 and a stop loss of ₹9,050. The stock is in an overall uptrend, trading near all-time highs, respecting its 10 EMA, and showing buying interest with a bullish Marubozu candle, suggesting a move towards fresh highs above ₹9,300.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
| “Bullish on Divi's Laboratories for the medium term, with a target price of ₹8,300. The company is positioned as a CDMO l…” | Rahul GhoseHedged.in | Divi's Laboratories | PENDING | ||||
Fundamentals
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Headquarters
Hyderabad
Employees
11,565
Website
divislabs.comExchange
View on NSE ↗Key stats
Market cap
₹2.47 L Cr
P/E ratio (TTM)
83.3
Dividend yield
0.33%
EPS (TTM)
₹111.88
Beta (1Y · daily vs NIFTY 50)
0.63
Beta (5Y · monthly vs NIFTY 50)
0.81
Shares float
11.73 Cr
EPS · quarter ended Jun 2026
₹33.95
Upcoming earnings
31 Oct 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 1.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,969.40 Cr | ₹8,959.83 Cr | ₹7,767.51 Cr | ₹7,845.00 Cr | ₹9,360.00 Cr | ₹10,560.00 Cr | |
| EBITDA | ₹2,922.50 Cr | ₹3,995.81 Cr | ₹2,712.48 Cr | ₹2,544.00 Cr | ₹3,320.00 Cr | ₹3,874.00 Cr |
| ₹1,984.29 Cr | ₹2,960.45 Cr | ₹1,823.38 Cr | ₹1,600.00 Cr | ₹2,191.00 Cr | ₹2,568.00 Cr | |
| Diluted EPS | ₹74.75 | ₹111.52 | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,774.07 Cr | ₹13,374.71 Cr | ₹14,438.77 Cr | ₹15,460.00 Cr | ₹16,921.00 Cr | ₹20,019.00 Cr | |
| ₹4.48 Cr | ₹3.69 Cr | ₹3.26 Cr | ₹3.00 Cr | ₹4.00 Cr | ₹7.00 Cr | |
| Stockholders' equity | ₹9,294.61 Cr | ₹11,728.18 Cr | ₹12,767.09 Cr | ₹13,571.00 Cr | ₹14,969.00 Cr | ₹16,761.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,946.93 Cr | ₹1,911.80 Cr | ₹2,460.00 Cr | ₹1,261.00 Cr | ₹1,653.00 Cr | ₹2,738.00 Cr | |
| Investing cash flow | ₹75.13 Cr | ₹-2,194.92 Cr | ₹-2,707.62 Cr | ₹-269.00 Cr | ₹-804.00 Cr | ₹-2,219.00 Cr |
| ₹-34.89 Cr | ₹-532.44 Cr | ₹-797.00 Cr | ₹-799.00 Cr | ₹-799.00 Cr | ₹-804.00 Cr | |
| Capital expenditure | ₹-956.03 Cr | ₹-713.20 Cr | ₹-473.02 Cr | ₹-1,003.00 Cr | ₹-1,438.00 Cr | ₹-2,520.00 Cr |
| End cash position | ₹2,030.32 Cr | ₹1,214.76 Cr | ₹169.70 Cr | ₹363.00 Cr | ₹413.00 Cr | ₹128.00 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Mar 23(5Q) | Jun 23–Sep 23(2Q) | Dec 23–Mar 24(2Q) | Jun 24 | Sep 24–Sep 25(5Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 51.95% | 51.94% | 51.93% | 51.92% | 51.90% | 51.89% | 51.88% |
| Public | 48.05% | 48.06% | 48.07% | 48.08% | 48.10% | 48.11% | 48.12% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Aurobindo Pharma Limited | ₹97,238.87 Cr | ₹1,734 | 26.4 | 2.57 | 9.2% | 0.21 | +6.4% | +53.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 25
Concall transcripts
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
24 indices
Weight is a free-float market-cap-share estimate from NSE’s live index data, not NSE’s own published (and sometimes capped) index weight. Indices without a live weight feed are listed without one, in alphabetical order after the weighted ones.